Federal Register of Legislation
National Health Amendment (Pharmaceutical Benefits Scheme) Act 2012
No. 87, 2012
An Act to amend the National Health Act 1953, and for related purposes
Contents 1 Short title 2 Commencement 3 Schedule(s) Schedule 1—Approved ex‑manufacturer price Part 1—Amendments National Health Act 1953 Part 2—Application, saving and transitional provisions Division 1—Preliminary Division 2—Converting approved price to pharmacists to approved ex‑manufacturer price of brands of pharmaceutical items (other than single brands of combination items) Division 3—Converting approved price to pharmacists to approved ex‑manufacturer price of single brands of combination items Division 4—Converting claimed prices of brands of pharmaceutical items Division 5—Other Schedule 2—Price disclosure Part 1—Amendments National Health Act 1953 Part 2—Application provision Schedule 3—Prescriber bag supplies Part 1—Amendments National Health Act 1953 Part 2—Application, saving and transitional provisions
National Health Amendment (Pharmaceutical Benefits Scheme) Act 2012 No. 87, 2012
An Act to amend the National Health Act 1953, and for related purposes
[Assented to 28 June 2012]
The Parliament of Australia enacts:
1 Short title This Act may be cited as the National Health Amendment (Pharmaceutical Benefits Scheme) Act 2012.
2 Commencement This Act commences on 1 October 2012.
3 Schedule(s) Each Act that is specified in a Schedule to this Act is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this Act has effect according to its terms.
Schedule 1—Approved ex‑manufacturer price
Part 1—Amendments
National Health Act 1953
1 Subsection 84(1) Insert: approved ex‑manufacturer price of a listed brand of a pharmaceutical item means: (a) if a price agreement is in force in relation to the brand of the pharmaceutical item—the amount in force under the agreement as the amount that is, for the purposes of this Part, taken to be the appropriate maximum price of the brand of the pharmaceutical item; or (b) if a price determination is in force in relation to the brand of the pharmaceutical item—the amount in force under the determination as the amount that is, for the purposes of this Part, taken to be the appropriate maximum price of the brand of the pharmaceutical item.
We try to embed the page this law was scraped from. If the site blocks framing, you still get the link and a local excerpt.
Last checked with source on —
Checking whether the official page can be embedded…
Plain-English simplify of this law: a short summary, key points, and both sides of the argument. Generated on first view via Replicate, then cached. Vote on what helps your study.
No study brief is cached for this law yet. Sign up to generate a plain-English brief.
Sign up to generate